immune evaluation

PreclinicalBiologic

IIstituto Clinico Humanitas

immune evaluation is one of 29 biologic programs targeting Prostate Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Ifex

BBaxter Healthcare Corporation

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

Active, not recruiting·IIstituto Clinico Humanitas·N/A·NCT04624828·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for immune evaluation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — immune evaluation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for immune evaluation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IIstituto Clinico Humanitas

immune evaluation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News